Skip to content

Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on pharmacological therapies for alcohol use disorder and the nature of results and conclusions of these reviews

Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on pharmacological therapies for alcohol use disorder and the nature of results and conclusions of these reviews - AUD-FCOI

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039111
Enrollment
40
Registered
2020-01-10
Start date
2020-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Interventions

None listed

Sponsors

Oklahoma State University Center for Health Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligibility Criteria: To be included in our study, the study design must be a systematic review and or meta-analysis. We will use the PRISMA P deNAfinition of a systematic review meta-analysis, which states that a systematic review is a systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. 1. Furthermore, studies will be included if they compare at least one pharmacologic therapy to another (or in combination) or if they compare a pharmacologic therapy to an nonpharmacologic therapy, such as verbal alcoholism therapy. We will include all pharmacologic therapies, regardless of whether they are indicated for treatment of AUD (acamprosate, naltrexone, and disulfiram) or whether they are used off label. We will include studies along the following stages of progression: (i) stabilization following excessive use of alcohol, (ii) relapse prevention, or (iii) recovery maintenance. Furthermore, to qualify for inclusion, systematic reviews must have been published between September of 2016 and December of 2019. Only systematic reviews published in English and reviews that synthesize studies of human or animal data will be included.

Exclusion criteria

Exclusion criteria: Eligibility Criteria: To be included in our study, the study design must be a systematic review and or meta-analysis. We will use the PRISMA P deNAfinition of a systematic review meta-analysis, which states that a systematic review is a systematic review is a review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies. Meta-analysis refers to the use of statistical techniques in a systematic review to integrate the results of included studies. 1. Furthermore, studies will be included if they compare at least one pharmacologic therapy to another (or in combination) or if they compare a pharmacologic therapy to an nonpharmacologic therapy, such as verbal alcoholism therapy. We will include all pharmacologic therapies, regardless of whether they are indicated for treatment of AUD (acamprosate, naltrexone, and disulfiram) or whether they are used off label. We will include studies along the following stages of progression: (i) stabilization following excessive use of alcohol, (ii) relapse prevention, or (iii) recovery maintenance. Furthermore, to qualify for inclusion, systematic reviews must have been published between September of 2016 and December of 2019. Only systematic reviews published in English and reviews that synthesize studies of human or animal data will be included.

Design outcomes

Primary

MeasureTime frame
Objectives: Our primary objectives are (i) to characterize the nature and types of conflicts of interest (both disclosed and undisclosed) of systematic review authors and (ii) to determine whether the direction of meta-analytic pooled effect estimates, when provided, and narrative results and conclusions from systematic reviews may be influenced by having systematic review authors with conflicts of interest. Our secondary objectives will be to evaluate whether an association exists between risk of bias and financial conflicts of interest of systematic review authors

Secondary

MeasureTime frame
(ii) whether a relationship exists between sponsorship of systematic reviews and their reported results and conclusions.

Countries

North America

Contacts

Public ContactMatt Vassar

Oklahoma State University Center for Health Sciences Department of Psychiatry and Behavioral Sciences

matt.vassar@okstate.edu9185821972

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026